Psychedelic Therapies for Comorbid Major Depressive Disorder and Chronic Pain: A Review of Putative Mechanisms of Action
Pharmacology Research & Perspectives · 2026-04 · 14 (2)
DOI: 10.1002/prp2.70238 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacology Research & Perspectives, online erschienen am 06.04.2026. Verfasst von Jordana Kazdan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Major Depressive Disorder, Chronic Pain, Hallucinogens. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Schmerzmanagement
Abstract (Originalsprache)
Major Depressive Disorder (MDD) and chronic pain are independently debilitating conditions that frequently co‐occur. This comorbidity poses a significant clinical challenge, resulting in greater symptom severity, higher disability, and worse prognosis than either condition alone. Current therapies often address each disorder in isolation, leaving individuals with comorbid MDD and chronic pain underserved. Serotonergic psychedelics such as psilocybin, N,N‐dimethyltryptamine (DMT), and Lysergic Acid Diethylamide (LSD) have reemerged as promising therapeutic targets for a range of neuropsychiatric disorders. When combined with psychological support, psychedelics show rapid and sustained antidepressant potential, and preliminary evidence supports analgesic effects. Despite substantial overlap in the biological and psychological processes underlying MDD and chronic pain, research on psychedelics for this comorbidity remains largely unexplored. This narrative review examines putative mechanisms through which psychedelics target symptoms of both MDD and chronic pain. Mechanisms considered include serotonergic modulation via the 5‐HT2A receptor, anti‐inflammatory effects, neuroplastic changes, altered brain network dynamics, psychological effects, and the influence of set and setting. While most existing evidence comes from populations with either depression or pain alone, the breadth of proposed mechanisms supports psychedelics as a unified therapeutic approach for comorbid MDD and chronic pain. This review provides a compelling rationale for future clinical trials to evaluate psychedelic‐assisted therapies for complex neuropsychiatric and medical conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Temerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health, Toronto, Ontario, Canada.
- Pharmacology and Toxicology, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
- Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, Ontario, Canada.
- Department of Anesthesia, Women's College Hospital, Toronto, Ontario, Canada.
- Krembil Brain Institute and Centre for Mental Health, United Health Network, Toronto, Ontario, Canada.
- Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
ORCID-Profile: Jordana Kazdan
Zitieren
APA
Kazdan, J., Ladha, K. S., & Husain, M. I. (2026). Psychedelic Therapies for Comorbid Major Depressive Disorder and Chronic Pain: A Review of Putative Mechanisms of Action. Pharmacology Research & Perspectives, 14(2). https://doi.org/10.1002/prp2.70238
Vancouver
Kazdan J, Ladha KS, Husain MI. Psychedelic Therapies for Comorbid Major Depressive Disorder and Chronic Pain: A Review of Putative Mechanisms of Action. Pharmacology Research & Perspectives. 2026;14(2). doi:10.1002/prp2.70238
BibTeX
@article{Kazdan2026,
author = {Kazdan, Jordana and Ladha, Karim S and Husain, M Ishrat},
title = {Psychedelic Therapies for Comorbid Major Depressive Disorder and Chronic Pain: A Review of Putative Mechanisms of Action},
journal = {Pharmacology Research & Perspectives},
year = {2026},
volume = {14},
number = {2},
doi = {10.1002/prp2.70238}
}
EUVIMED